Abstract:Background: Antimicrobial peptides (AMPs) are promising alternative agents for antibiotics to overcome antibiotic resistance problems. But, it is difficult to produce large-scale antimicrobial research due to the toxicity towards expression hosts or degradation by peptidases in the host. Therefore, heterologous recombinant expression of antimicrobial peptides has always been a challenging issue. Objectives: To overcome toxicity to the expression host and low expression level, a new photocleavable protein fusion expression method for antimicrobial peptides is provided. Methods: Through directed evolution and high throughput screening, a photocleavable protein mutant R6-2-6-4 with a higher photocleavage efficiency was obtained. The DNA coding sequence of antimicrobial peptide Histatin 1 was fused within the sequence of R6-2-6-4 gene. The fusion gene was successfully expressed in Escherichia coli expression system. Results: Antimicrobial peptide Histatin 1 could be successfully expressed and purified by fusing within PhoCl mutant R6-2-6-4. The antimicrobial activity was rarely affected, and the MIC value was 33 ug/mL, which was basically equivalent to 32 ug/mL of the chemically synthesized Histatin 1. After amplification in a 5 L fermenter, the expression of PhoCl mutant (R6-2-6-4)-Histatin1 improved up to 87.6 mg/L in fermenter, and Histatin1 obtained by photocleavage also could up to 11 mg/L. The prepared Histatin1 powder remained stable when stored at 4oC for up to 4 months without any degradation. In addition, the expression and photocleavage of β -Defensin105 and Lysostaphin verified the certain universality of the PhoCl mutant fusion expression system. Conclusion: Antimicrobial peptides Histatin 1, β -Defensin 105 and Lysostaphin were successfully expressed and purified by photocleavable protein mutant. This may provide a novel strategy to express and purify antimicrobial peptides in the Escherichia coli expression system.

De Novo Development of Proteolytically Resistant Therapeutic Peptides for Oral Administration

Towards the Development of Orally Available Peptide Therapeutics.

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform

Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches

Progress in the Study of Oral Delivery of Protein and Peptide Drugs

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Systemic delivery of proteins using novel peptides via the sublingual route

Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

Nano and Microscale Delivery Platforms for Enhanced Oral Peptide/protein Bioavailability.

Improving Photocleavage Efficiency of Photocleavable Protein for Antimicrobial Peptide Histatin 1 Expression

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide

Preclinical proof of principle for orally delivered Th17 antagonist miniproteins

Molecular design of peptide therapeutics via N-terminal modification

Overcoming the shortcomings of peptide-based therapeutics

Nano and microscale delivery platforms for enhanced oral peptide/protein bioavailability

Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model

Analysis of modular bioengineered antimicrobial lanthipeptides at nanoliter scale

Antifungal activity of a de novo synthetic peptide and derivatives against fungal food contaminants

Design and Synthesis of New N-terminal Fatty Acid Modified-Antimicrobial Peptide Analogues with Potent in Vitro Biological Activity.